Denovo_Banner
Management Advisors Pipeline News Publications Contact Us 中文

Management

Wen Luo, Ph.D. - Chief Executive Officer, Chief Scientific Officer

Wen_Luo_Pic.jpg

Dr. Wen Luo has over 20 years of experience in biomedical research and industry including more than 15 years of experience in applying genomic technology in drug discovery and development. Prior to founding Denovo Biopharma, Dr. Luo managed the genomic group and provided bioinformatic support to a broad range of research projects across a number of therapeutic areas including oncology, hematology, inflammation and metabolic diseases at Ligand Pharmaceuticals. He was also responsible for developing clinical biomarkers for drugs in various stages of clinical trials. Before joining Ligand, he was a senior scientist for bioinformatics at Incyte Genomics, where he managed one of the largest proteomic databases, LifePro. He was also involved in discovering novel human genes and splice variants, and was the co-inventor of patents covering hundreds of novel genes derived from these findings. Prior to Incyte Genomics, he was a research scientist at Sugen, which had been acquired by Pharmacia, where he worked on drug target identification and validation for a number of novel kinases discovered at Sugen. Dr. Luo was a Howard Hughes Medical Institute post-doc fellow at the University of California, San Francisco, and received his Ph.D. in Molecular Biology and Biochemistry from Indiana University School of Medicine. Dr. Luo received pre-med training at Peking University and medical training at Peking Union Medical College.





Michael Haller, Ph.D. - Chief Business Officer

Michael_Haller_Pic.jpg

Dr. Haller has broad experience in the pharmaceutical and biotechnology industries, with leadership roles in business development and alliance management, finance and accounting, and corporate and product strategy. He currently leads the Business Development and Finance and Accounting teams at Denovo Biopharma. Prior to Denovo, he was Chief Business Officer, responsible for business development, finance, and accounting at Peloton Therapeutics. As Vice President of Business Development and Alliance Management at Ligand Pharmaceuticals, Dr. Haller was responsible for out-licensing activities and managing Ligand’s numerous alliances. Prior to Ligand, he was Senior Vice President of Strategic Partnerships at Anaphore, now Bird Rock Bio. He joined Anaphore from Halozyme Therapeutics, where he directed key alliances with Roche and Baxter Healthcare from deal signing through registration submissions, which resulted in several approved drugs, including Herceptin SC®, Mabthera SC®, and HyQvia®. He also served as head of Halozyme’s drug delivery franchise, Enhanze Technology. Prior to Halozyme, Dr. Haller was a McKinsey & Company management consultant focusing on complex health care issues for a number of Fortune 500 companies. Dr. Haller has published several peer-reviewed articles, presented at numerous scientific conferences, and is co-inventor on multiple patents. Dr. Haller earned his Ph.D. in Biomedical Engineering from The Johns Hopkins University School of Medicine, his MS in Chemical Engineering from Cornell University and his B.S. in Biomedical Engineering from The Johns Hopkins University.




Xiao-Xiong Lu, Ph.D. - Chief Technical Officer

XiaoXiong_Lu_Pic.jpg

Dr. Xiao-Xiong Lu has over 30 years of experience in the US biotech and pharmaceutical industries including extensive experience in pharmaceutical CMC development, manufacturing and supply chain. He has also consulted for a number of biotech and pharmaceutical companies worldwide in the areas of pharmaceutical CMC and business development. In February 2018, Dr. Lu joined Denovo Biopharma as Chief Technical Officer and is currently responsible for the company’s CMC, Regulatory Affairs, and Quality Assurance functions. Prior to joining Denovo, he served as Vice President of Technical Operations at Balance Therapeutics with responsibility for pharmaceutical CMC development, manufacturing and supply chain. From 2003 to 2015, he was with Arena Pharmaceuticals, most recently as Associate VP of CMC Technical Operations as well as Managing Director for Greater China. At Arena, Dr. Lu led or made significant contributions to the CMC activities and functions for BELVIQ® (lorcaserin) for obesity, temanogrel for thrombosis, nelotanserin for sleep disorders, ralinepag for PAH, etrasimod for autoimmune diseases, and olorinab for pain. From 1990 to 2003, he worked at Monsanto Company and its spin-off Solutia Inc. with increasing responsibilities in R&D and manufacturing. He received his Ph.D. from University of Birmingham in the UK and BSc from University of Petroleum in China, in Chemical Engineering.





Carrie Chen CFA,CPA – Chief Financial Officer

Carrie_Chen_Pic.jpg

Chen has more than 20-year experience in US, China, and Hong Kong capital markets. Before joining Denovo Biopharma, Chen was the Lead Partner of Asia pacific life science and healthcare industries at Deloitte. Prior, Chen served as a Senior Vice President at CITIC Securities Investment Banking Committee. Major capital market achievements including: initiated a number of cross border M&As with over USD$1B deal size, advised major domestic capital restructuring projects, led US listed companies re-listed in A share, and advised companies listed at the A/H market. Chen holds an MBA degree with dual majors at Leverage Buyout and Business Strategy from Wharton School at the University of Pennsylvania, and an undergraduate degree in Business Administration, majoring in Accounting from National Cheng-Chi University. Chen is a chartered financial analyst (CFA) and also passed US CPA, Mainland China CPA as well as Taiwan CPA exams early 2000.








Xiangming Fang, M.D., Ph.D. - Chief Operating Officer

XiangMing_Fang_Pic.jpg

Dr. Fang has 20+ years of experience in biomedical research and product development. She has a strong scientific background with integrated knowledge in medicine, molecular and cell biology, immunology, genomics and proteomics. She was also involved in several startup companies where she gained experience in team building and operations. Previously as the Senior Vice President and Chief Scientific Officer at GenWay Biotech, she was responsible for new technology and product development and production, as well as customer support and partnership coordination. Prior to GenWay, Dr. Fang served at GenStar Therapeutics, initially as the Director of the Cancer Program and the Director of Preclinical Studies, then as Vice President, Hemophilia and Vector Development. Dr. Fang's earlier experience includes gene therapy product development for hemophilia at Baxter Healthcare and GeneMedicine Inc. Dr. Fang obtained her M.D. from Zhejiang University Medical School and Ph.D. in Molecular Biology from the University of Alabama. She completed her postdoctoral studies at the University of Texas, MD Anderson Cancer Center. Dr. Fang was the President (2009-2010) of Sino-American Biomedical and Pharmaceutical Professionals Association (SABPA), San Diego chapter, and currently serves as Vice Chair of Board of Directors.





Thomas Heineman – Senior Vice President, Clinical Development

Tom Heineman photo.jpg

Dr. Thomas Heineman has over 25 years’ experience in biomedical research and a strong medical and scientific background with integrated knowledge of clinical medicine, molecular and cellular biology, immunology and biomarker discovery in oncology, hematology, immuno-oncology and vaccines. Prior to Denovo, Dr. Heineman was Vice President and Head of Clinical Development and Translational Medicine at Halozyme Therapeutics where he led the evaluation of PEGPH20 in oncology, along with its tissue- and plasma-based biomarkers. Before Halozyme, Dr. Heineman was Vice President and Head of Clinical Development at Genocea Biosciences where he led the development of both cancer and infectious disease vaccines. Dr. Heineman began his career in the pharmaceutical industry with 10 years at GlaxoSmithKline, where he was the clinical lead for multiple assets and led clinical trials enrolling more than 40,000 subjects including the global development of Shingrix, GSK’s approved shingles vaccine. Prior to entering the pharmaceutical industry, Dr. Heineman was a tenured professor of medicine at Saint Louis University where he conducted clinical and basic research and served as an attending physician. Dr. Heineman received his M.D., Ph.D. in molecular genetics and M.S. in biochemistry from the University of Chicago. He did his medical residency at the University of Maryland and received fellowship and post-doctoral training at the U.S. National Institutes of Health.




Wilson Wu - Senior Vice President, Biometrics

Wilson Wu Photo.jpg

Dr. Wu joined Denovo Biopharma as Senior Vice President of Global Biometrics in January 2020. Dr. Wu has 20 years of experience in drug development and clinical research, 15 years of management experience in building Biometrics teams (Biostatistics, Programming, and Data Management). , and significantly contributed to the approval of three drugs in US, Europe, and other regions. Dr. Wu is a subject matter expert in innovative trial designs, statistical methodology, and effective use of modeling and simulations in accelerating drug development, optimizing product life cycle management, and driving quantitative evidence-based decision making. He had extensive interactions with FDA on adaptive Phase 3 oncology trial design, registration strategy, and breakthrough application. Prior to joining Denovo, Dr. Wu served as Vice President of Biometrics for Halozyme Therapeutics. Prior to Halozyme, he served as Therapeutics Area Statistical Head of Infectious Diseases and Vaccines for AstraZeneca and held progressive leadership roles at Pfizer. Dr. Wu received his Ph.D. in Biostatistics from University of Texas Health Science Center at Houston, M.S. in Statistics from Texas A&M University, and M.S. in Genetics from Jinan University in China. Dr. Wu also has a Certificate in Regulatory Affairs from San Diego State University.





Joe Zimmerman - Senior Vice President Global Clinical Operations

Zimmerman.png

Mr. Zimmerman has over 30 years of experience in drug development and clinical research, including leadership roles in global clinical operations, business operations, medical and pre-clinical operations. His prior roles included Vice President Global Development Operations with Sanifit Inc, Vice President Oncology Clinical Operations with Halozyme, Vice President Clinical Operations with Spectrum Pharmaceuticals, and Vice President Global Operations with invivodata, inc. Mr. Zimmerman has led operational and business organizations in small and medium-sized biotech companies, as well as with contract research organizations (Covance) and vendor (invivodata) companies. He has led the conduct of clinical research trials from phase I to a 10,000 patient phase IV outcomes trial. Mr. Zimmerman obtained his BS in biology from Drexel University and his MBA from Villanova University in the Philadelphia PA area.






Isabel Han - Vice President, Clinical Operations & Site Head, Denovo China Office

Isabel_Han_Pic.jpg

Isabel has more than 20 years of experience in the clinical operations of global pharmaceutical companies and Contract Research Organizations (CROs). Isabel joined Denovo in September 2016. As VP of Clinical Operations and Denovo’s China site head, Isabel is responsible for the Chinese portion of global clinical development strategy and ensuring operational implementation in China. Prior to Denovo, Isabel was Director, Head of Operations, Clinical Development Service for Covance China where she spent eight years in key leadership roles and led the creation of Covance’s clinical operations team in China. Before her tenure at Covance, Isabel worked in multiple companies including Actelion, AstraZeneca, Boehringer Ingelheim, and Kirin Pharmaceuticals. Isabel received her Bachelor’s Degree of Medical Science from Peking University Health Science Center.





About Us

Denovo Biopharma is a privately held biotech company providing a novel biomarker solution to personalize drug development. Our platform can be broadly applied to biomarker discovery in many therapeutic areas, such as oncology, metabolic, cardiology, immunology and neurology.

Network with Us

LI-In-Bug.pngFollow Us

Contact Us